Across different cohorts, low ploidy 📉 and high heterogeneity 📈 robustly identify patients with intrinsic resistance to aPD-1 therapy
Across different cohorts, low ploidy 📉 and high heterogeneity 📈 robustly identify patients with intrinsic resistance to aPD-1 therapy